Elorac

Elorac receives FDA Fast Track designation for naloxone for pruritus

Wednesday, April 17, 2013

Elorac, a specialty pharmaceutical company focused on the treatment of dermatological disorders, has been granted Fast Track designation by the FDA for its naloxone topical lotion for the relief of pruritus in patients with cutaneous T-cell lymphoma (CTCL). There are currently no approved therapeutic treatment options available to patients and their physicians for pruritus in CTCL.

[Read More]